ArticleArchives of toxicology2026
Physiologically based pharmacokinetic modeling of polychlorinated biphenyl-153: cross-species extrapolation and human exposure simulation.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polychlorinated biphenyl-153 (PCB-153) is a representative organic pollutant that can accumulate in the human body, particularly in adipose tissue, for long periods due to its environmental persistence and high lipid solubility. Existing risk assessments primarily rely on simple extrapolations based on blood concentrations, and a quantitative approach that considers internal exposure at the tissue level is lacking. The main objective of this study was to establish a human physiologically based pharmacokinetic (PBPK) model for PCB-153 and to quantitatively predict tissue accumulation in the human body based on this model, thereby suggesting the possibility of expanding its application as a precise and scientific human risk assessment tool in the future. Based on existing mouse experimental data, a PBPK model was constructed and validated, and a whole-body human PBPK model was established through interspecies extrapolation. Monte Carlo simulations were then performed, considering physiological variations in the adult population, to predict concentration-time curves for major human tissues (fat, liver, brain, skin, and plasma) following a single dose (20 mg/kg) and repeated exposures at the reference dose (RfD) level (5.86 ng/kg/day). The simulation results based on the human PBPK model established in this study showed that adipose tissue showed the highest accumulation pattern with an average partition coefficient (K
Indexed as
Identifiers
41454111What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.